Naslov
AFP-L3 - SCREENING MARKER FOR A HEPATOCELLULAR CARCINOMA IN PATIENTS WITH ALCHOCOLIC CIRRHOSIS

Autori
Unić, Adriana ; Grgurević, Ivica ; Đerek, Lovorka ; Marijančević, Domagoj ; Serdar, Tihana ; Romić, Željko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Biochimica Clinica / Panteghini, Mauro - Brescia : Società Italiana di Biochimica Clinica (SIBioC), 2013

Skup
20th IFCC EFCC European Congress of Clinical Chemistry and Laboratory Medicine

Mjesto i datum
Milano, Italija, 19.05.2013. - 23.05.2013

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
hcc, AFP-L3, accuracy

Sažetak
Background: Hepatocellular carcinoma (HCC) is the most common complication of liver cirrhosis. Screening of patients with cirrhosis is necessary to confirm the diagnosis of HCC in an early phase of the limited and small tumor. The recommended monitoring strategy in patients with cirrhosis is still based on ultrasound examination and determination of αfetoprotein (AFP) in the serum. The limitations of ultrasound diagnostics are the inability to distinguish HCC from hemangioma and cirrhotic nodules, limited sensitivity to detect small tumors as well as the impact of human factor. On the other hand, AFP tumor marker has a low specificity. Considering that, it is necessary to find and evaluate new serum and molecular markers for monitoring high risk population as well as for early diagnosis of HCC. The aim of this study was to evaluate whether the determination of AFPL3 isoforme can improve early non-invasive diagnosis of HCC. Materials and Methods: Sera samples from 32 patients with HCC with a background of alcoholic liver disease (ALD) as well as 28 sera samples from age adjusted alcohol related cirrhosis control group, were assessed by specific ELISA assay for AFPL3 (Cusabio Biotech CO., LTD. Wuhan, P.R.China). AFP concentrations were determined using Cobas e411 (Hitachi High Technologies Corporation, Tokyo, Japan) analyzer. The diagnostic accuracy of each biomarker was evaluated using receiver operating characteristic (ROC) curve analysis reporting the area under the curve (AUC) and its 95% confidence interval (CI). Results: Our results showed that AFP concentration of 14.62 ng/mL distinguishes patients with HCC and patients with liver cirrhosis with diagnostic sensitivity of 68, 75% and 100% diagnostic specificity. AFP-L3 concentration of 4.26 ng/mL distinguishes tested groups with diagnostic sensitivity of 75% and 100% diagnostic specificity. AUC (95% CI) for AFP was 0.888 (0.781-0.955), and for ALP-L3 0.929 (0.832-0.979). Conclusion: Our study indicates that AFP-L3 is an improvement in HCC screening of high risk ALD patients in relation to AFP due to better diagnostic sensitivity and higher AUC.

Izvorni jezik
Engleski

POVEZANOST RADA